Drug Serialization in Canada: The Traceability Requirements Your Pharma Supply Chain Cannot Ignore

When a subpotent blood thinner reaches a hospital pharmacy in Winnipeg and a Class I recall gets issued, the clock starts immediately. Health Canada’s recall coordinators begin tracing affected product — which wholesale distributors received which lot numbers, which hospitals placed orders, and how much product remains in inventory versus already dispensed to patients. In a supply chain that still relies heavily on paper manifests and manually checked lot records, that trace can take days when it should take hours.

Pharmaceutical serialization exists precisely to collapse that timeline. And while Canadian manufacturers haven’t faced the same hard legislative deadlines that US counterparts dealt with under the Drug Supply Chain Security Act (DSCSA), the pressure to implement unit-level traceability is now arriving from multiple directions at once — export market obligations, hospital purchasing requirements, and increasingly probing Health Canada GMP inspections among them.

Where Canada’s Drug Traceability Framework Currently Stands

The foundation of Health Canada’s approach to drug traceability is the Food and Drugs Act and its associated regulations, supplemented by guidance documents governing distribution practices and bar coding. Health Canada’s Good Distribution Practices guidance (GUI-0069) requires DEL (Drug Establishment Licence) holders — including importers, distributors, and manufacturers — to maintain distribution records capable of supporting a targeted recall at any point in the supply chain.

Under that requirement, if Health Canada requests it, you should be able to produce a complete list of direct customers who received a specific lot within one working day. That’s the standard. What GUI-0069 doesn’t mandate is how you achieve that traceability. Paper batch records and manual shipping logs can technically satisfy it, provided they’re consistently maintained and can actually be retrieved under pressure. That latitude is exactly where most manufacturers’ traceability gaps live.

Canada does have a published pharmaceutical barcode standard, developed collaboratively with GS1 Canada, that defines how product identifiers should appear on outer and inner packaging. The standard uses GTIN-based (Global Trade Item Number) codes — the same GS1 architecture used globally — and specifies which packaging levels require machine-readable symbologies. Compliance has been largely voluntary and industry-driven. Hospital group purchasing organizations and retail pharmacy chains have pushed adoption faster than formal regulation has, particularly for products entering hospital formularies.

What Canada doesn’t yet have is a mandatory, interoperable unit-level serialization requirement with legislated deadlines — equivalent to the US DSCSA or the EU’s Falsified Medicines Directive, which has covered over 30 European markets since 2019. Health Canada has signalled it’s monitoring both frameworks closely, and internal consultations on enhanced supply chain integrity measures have been ongoing. But as of mid-2026, no mandatory serialization regulation has been promulgated under Canadian law.

That won’t hold indefinitely. The regulatory direction globally is clear, and Health Canada’s compliance posture is trending toward it.

How the US DSCSA Is Already Reshaping Canadian GMP Sites

If you manufacture drugs destined for the US market — whether as a Canadian CMO doing contract manufacturing for US sponsors, or as a manufacturer with your own US distribution arrangements — the DSCSA applies to your product regardless of where it was made.

The DSCSA’s full interoperable tracing requirements came into force on November 27, 2023, following a one-year stabilization period that FDA granted after industry raised readiness concerns. Under the law, every prescription drug package sold in the US must carry a product identifier encoding four data elements in a standardized 2D barcode — either GS1 DataMatrix or GS1-128: the National Drug Code (NDC), a unique serial number, the lot number, and the expiration date. Trading partners throughout the supply chain — manufacturers, repackagers, wholesale distributors, and dispensers — must exchange Transaction Information (TI), Transaction History (TH), and Transaction Statements (TS) with each sale.

For Canadian CMOs, this creates documentation obligations that don’t stop at the border. If your facility manufactures a product that your US sponsor commercializes, your packaging systems and batch records need to generate and maintain the serialization data that appears on that product identifier — and you need to be able to produce it on demand during an FDA inspection or a DSCSA supply chain investigation.

We’ve seen this catch facilities off guard. A site might have a strong Canada GMP program — compliant change control, validated cleaning procedures, well-maintained equipment qualification documentation — but its serialization data architecture is fragmented or ad hoc. When the US sponsor’s regulatory team asks for a serialization data extract during a DSCSA compliance audit, the gaps surface quickly, and the remediation timeline is rarely comfortable.

The cost of retrofitting serialization hardware and software into an existing production line is significant. Industry estimates for a mid-size solid oral dosage facility range from $500,000 to well over $2 million CAD, depending on the number of packaging lines, packaging format complexity, and whether existing line infrastructure can accommodate inline vision systems and print-apply equipment. Building readiness in at the design stage — or during planned line upgrades — is considerably cheaper than a forced retrofit under regulatory pressure.

What Health Canada GMP Inspectors Are Actually Looking For Today

Even without a Canadian serialization mandate, Health Canada GMP inspectors are paying closer attention to traceability infrastructure during routine inspections and DEL renewals. The questions they’re asking have gotten more specific.

Under Canada GMP, batch records must support complete traceability of all raw materials, intermediates, and finished product throughout manufacturing and distribution. Inspectors are increasingly asking how a facility would trace a specific unit — not just a lot — back to its source if a field safety corrective action became necessary. They want to see SOPs for distribution record retrieval. They want evidence that your system can produce a compliant distribution trace within 24 hours. And they want to verify that the people responsible for executing that trace have actually practiced it.

If your facility uses a computerized inventory or shipping management system, Health Canada inspectors scrutinize it through the department’s data integrity guidance framework. Any system that generates, stores, or transmits distribution records or batch data falls within the scope of computerized system validation under Canada GMP. The ALCOA+ principles — Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available — apply to electronic records whether they’re in a validated LIMS, a WMS, or a shared network drive that someone configured manually five years ago.

If your serialization or track-and-trace system is integrated with a warehouse management system or ERP platform, all of those integrations fall within the computerized system validation scope. This is where manufacturers routinely underestimate the GMP footprint of a serialization project. The packaging line hardware is what vendors demo. The data system validation, access control documentation, audit trail configuration, backup and recovery protocols, and periodic review requirements are what Health Canada inspectors actually examine in depth.

Building a Serialization Programme That Works for Both Health Canada and Export Markets

For Canadian manufacturers serving both domestic and US markets — or preparing for the eventuality of a Canadian requirement — the practical approach is to build once against the more demanding standard and ensure your Canada GMP documentation is structured to support it fully.

Start with a gap assessment covering three reference points simultaneously: Health Canada’s GUI-0069 distribution record requirements, GS1 Canada’s pharmaceutical barcode standard for each applicable packaging level, and FDA’s DSCSA requirements for your specific product types and supply chain roles. The overlap across these three is substantial, and treating them as three separate compliance tracks wastes considerable effort.

Your packaging line assessment should answer four questions clearly. Which packaging levels need barcodes — unit, inner, case, pallet? What data elements must be encoded at each level? Do your existing print systems support 2D Data Matrix codes with the required print quality grades? And what inline barcode verification capability do you have to catch print defects before product leaves the line?

The serialization data management layer is consistently the most underestimated piece. You need a Serialization Management System — sometimes called a Serialization Host or Level 3/4 system — capable of generating unique serial numbers, pushing commissioned numbers to packaging line controllers, receiving confirmed pack data back, aggregating across packaging levels, and transmitting aggregated pack data to US trading partners in EPCIS (Electronic Product Code Information Services) format. Each of those data flows needs to be defined, tested, and validated under Canada GMP requirements.

Personnel training is the final piece, and it’s easy to shortchange. Packaging operators who have worked with linear barcodes for years need to understand the significance of 2D codes and the GMP implications of specific failure modes — particularly “orphaned” serial numbers, where a number is generated but never confirmed as commissioned on a finished pack. That gap creates a reconciliation discrepancy requiring a deviation investigation record. Building that understanding into operator qualification and batch record training, rather than treating it as a brief onboarding note, is the difference between a serialization system that runs cleanly and one that generates a steady stream of documentation burden.

The Manufacturers Who Build Now Will Set the Pace

The Canadian pharmaceutical industry’s experience with other major regulatory transitions — enhanced NHP site licence requirements, the shift to electronic regulatory submissions, the progressive tightening of data integrity expectations — suggests consistently that waiting for a formal deadline and scrambling is the most expensive path. The compliance costs are real either way; the timing determines whether you’re in control of them.

Health Canada’s ongoing supply chain integrity consultations, combined with the immediate practical pressure of US DSCSA compliance for manufacturers with cross-border exposure, means unit-level drug serialization in Canada is a matter of when, not if. The sites that build compliant, validated serialization infrastructure now will move through customer audits and regulatory inspections more smoothly, and they’ll be positioned to meet whatever formal Canadian requirements eventually emerge without the premium that comes with urgency.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• ISO 17025 Accreditation for Pharmaceutical Testing — Qalitex Laboratories offers accredited analytical testing services for drug manufacturers seeking validated data for regulatory submissions.
• EU Falsified Medicines Directive and Serialization Requirements — Care Europe covers European pharmaceutical traceability obligations under the FMD and how they compare to North American standards.